CRISPR Therapeutics (NASDAQ:CRSP) PT Raised to $88.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective increased by Needham & Company LLC from $85.00 to $88.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other analysts have also recently weighed in on the stock. […]
More Stories
Thrivent Financial for Lutherans Boosts Holdings in Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG)
Thrivent Financial for Lutherans grew its stake in shares of Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG – Free Report)...
Thrivent Financial for Lutherans Purchases 1,101,796 Shares of iShares U.S. Treasury Bond ETF (BATS:GOVT)
Thrivent Financial for Lutherans boosted its position in iShares U.S. Treasury Bond ETF (BATS:GOVT – Free Report) by 280.3% in...
Swiss National Bank Cuts Stock Holdings in PulteGroup, Inc. (NYSE:PHM)
Swiss National Bank trimmed its holdings in shares of PulteGroup, Inc. (NYSE:PHM – Free Report) by 0.6% in the 3rd...
Swiss National Bank Buys 1,400 Shares of American Water Works Company, Inc. (NYSE:AWK)
Swiss National Bank raised its stake in shares of American Water Works Company, Inc. (NYSE:AWK – Free Report) by 0.2%...
Swiss National Bank Acquires 14,900 Shares of Corning Incorporated (NYSE:GLW)
Swiss National Bank boosted its holdings in shares of Corning Incorporated (NYSE:GLW – Free Report) by 0.6% in the 3rd...
Swiss National Bank Purchases 2,300 Shares of Entergy Co. (NYSE:ETR)
Swiss National Bank grew its position in shares of Entergy Co. (NYSE:ETR – Free Report) by 0.4% during the 3rd...